1. Home
  2. HURN vs IBRX Comparison

HURN vs IBRX Comparison

Compare HURN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

HOLD

Current Price

$171.30

Market Cap

2.8B

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.21

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HURN
IBRX
Founded
2002
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.3B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
HURN
IBRX
Price
$171.30
$2.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$190.25
$9.83
AVG Volume (30 Days)
123.7K
10.5M
Earning Date
10-28-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
32.32
N/A
EPS
5.98
N/A
Revenue
$1,618,977,000.00
$82,555,000.00
Revenue This Year
$14.19
$667.18
Revenue Next Year
$9.49
$88.32
P/E Ratio
$28.97
N/A
Revenue Growth
12.67
1025.95
52 Week Low
$118.25
$1.83
52 Week High
$174.26
$5.12

Technical Indicators

Market Signals
Indicator
HURN
IBRX
Relative Strength Index (RSI) 68.19 49.90
Support Level $157.52 $2.06
Resistance Level $173.69 $2.40
Average True Range (ATR) 4.58 0.14
MACD 0.50 0.02
Stochastic Oscillator 92.70 46.69

Price Performance

Historical Comparison
HURN
IBRX

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: